Cargando…

Targeting DNA methylation for treating triple-negative breast cancer

Triple-negative breast cancer (TNBC) accounts for 15–20% of all invasive breast cancers and tends to have aggressive histological features and poor clinical outcomes. Unlike, estrogen receptor- or HER2-positive diseases, TNBC patients currently lack the US FDA-approved targeted therapies. DNA methyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jia, Zayas, Jacqueline, Qin, Bo, Wang, Liewei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2019
Materias:	Special Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026764/ https://www.ncbi.nlm.nih.gov/pubmed/31755366 http://dx.doi.org/10.2217/pgs-2019-0078

Ejemplares similares

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
por: Si, Yingnan, et al.
Publicado: (2021)

DNA methylation data for identification of epigenetic targets of resveratrol in triple negative breast cancer cells
por: Medina-Aguilar, Rubiceli, et al.
Publicado: (2017)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2022)

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Meyer, Braydon, et al.
Publicado: (2021)

A DNA methylation-based liquid biopsy for triple-negative breast cancer
por: Cristall, Katrina, et al.
Publicado: (2021)

Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer
por: Kohale, Ishwar N., et al.
Publicado: (2022)

DNA methylation markers predict recurrence-free interval in triple-negative breast cancer
por: Fackler, Mary Jo, et al.
Publicado: (2020)

Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer
por: Behrens, Marshall D., et al.
Publicado: (2022)

Tumor protein D52 (TPD52) affects cancer cell metabolism by negatively regulating AMPK
por: Chen, Yali, et al.
Publicado: (2022)

DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid
por: Coyle, Krysta Mila, et al.
Publicado: (2018)

Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer
por: Gao, Yinqi, et al.
Publicado: (2021)

Methylation profile of triple-negative breast carcinomas
por: Branham, M T, et al.
Publicado: (2012)

Coupled Genome-Wide DNA Methylation and Transcription Analysis Identified Rich Biomarkers and Drug Targets in Triple-Negative Breast Cancer
por: Guo, Maoni, et al.
Publicado: (2019)

The Roles of DNA Demethylases in Triple-Negative Breast Cancer
por: Panjarian, Shoghag, et al.
Publicado: (2021)

Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer
por: Yang, Xu, et al.
Publicado: (2023)

A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis
por: Mendaza, Saioa, et al.
Publicado: (2021)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene
por: Butler, Christopher, et al.
Publicado: (2020)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Triple-negative breast cancer and the potential for targeted therapy
por: Jhan, Jing-Ru, et al.
Publicado: (2017)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses
por: Green-Tripp, Gabriela, et al.
Publicado: (2022)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer
por: Lin, Fei, et al.
Publicado: (2023)

The development of activatable lytic peptides for targeting triple negative breast cancer
por: Zhao, Hui, et al.
Publicado: (2017)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
por: Park, So-Yeon, et al.
Publicado: (2019)

DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer
por: Sigin, Vladimir O., et al.
Publicado: (2023)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

MYC and DNMT3A‐mediated DNA methylation represses microRNA‐200b in triple negative breast cancer
por: Pang, Yamei, et al.
Publicado: (2018)

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
por: Chen, Xi, et al.
Publicado: (2012)

Triple-Negative Lobular Breast Cancer Causing Hydronephrosis
por: Chahin, Michael, et al.
Publicado: (2020)

Management of triple negative breast cancer in a centenarian
por: Donaldson, Andrew, et al.
Publicado: (2022)

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
por: Yang, Ruoning, et al.
Publicado: (2022)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bkqefg30ec2t36rr4fjvfklh3d